Abstract
Objectives To evaluate the effects of a home-based pulmonary rehabilitation (PR) programme on anxiety and depressive symptoms, general fatigue and burden in informal caregivers of patients with COPD. We also evaluated the baseline characteristics of both patients and caregivers that contributed to the change in caregiver's outcomes after PR.
Methods In this retrospective study, patients with COPD were referred to an 8-week home-based PR programme consisting of a weekly supervised 90-minute session. Informal caregivers, according to the patient's preference and its availability, were invited to participate in PR. Caregivers received educational supports, behavioral therapies and self-management strategies using the same methods as for patients. Burden, anxiety and depressive symptoms and general fatigue of caregivers were assessed at baseline and at the end of PR.
Results 241 patients with COPD and 138 (57.3%) caregivers were included. The majority of the caregivers were women (70.5%), spouses (90.3%) and with at least three comorbidities (57.3%). A large proportion of caregivers showed baseline high burden, anxiety symptoms, and abnormal fatigue (40%, 40%, 45%, respectively). Burden, anxiety and depressive symptoms and general fatigue of informal caregivers were all improved after PR (p<0.05). Long-term oxygen therapy and/or non-invasive ventilation, coronaropathy and/or peripheral arterial disease and a higher baseline mMRC score in patients with COPD were associated with a decrease in caregiver's burden after PR.
Conclusion A large proportion of caregivers of patients with COPD showed anxiety symptoms, fatigue and a high burden. These outcomes were improved by integrating the caregiver into a home-based PR programme.
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Grosbois Jean Marie reports the following relationships outside the submitted work; The delivery of home-based PR was financially supported by Adair, Aeris Santé, Bastide, Elivie, France Oxygène, Homeperf, LVL, Médopale, NorOx, Santélys, Santéo, SOS Oxygène, Sysmed, VentilHome, VitalAire and ARS Hauts-de-France. The funders played no role in the design, conduct or reporting of this study; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Novartis and Roche, payments to declarant for Attending meetings and/or travel received from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Novartis and Roche; Other financial or non-financial interests details available on: https://www.transparence.sante.gouv.fr/. LE ROUZIC Olivier reports the following relationships outside the submitted work; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Novartis; support for attending meetings and/or travel received from Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Vitalaire; Participation on a Data Safety Monitoring Board or Advisory Board for JGM Health Conseils, payments to declarant. Other financial or non-financial interests details available on: https://www.transparence.sante.gouv.fr/.
Conflict of interest: Sarah Gephine has nothing to disclose.
Conflict of interest: Maeva Kyheng has nothing to disclose.
Conflict of interest: Olivier Le Rouzic has nothing to disclose.
Conflict of interest: Cécile Chenivesse reports the following relationships outside the submitted work; grants or contracts received from AstraZeneca and Santelys; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKlein, Novartis, Sanofi-Regeneron and TEVA support for attending meetings and/or travel received from ALK-Abello, AstraZeneca, Boehringer, Ingelheim, GlaxoSmithKlein, Novartis, Pierre Fabre, Pfizer, Roche and TEVA.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received May 23, 2022.
- Accepted September 11, 2022.
- Copyright ©The authors 2022
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org
